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A child living in the Brazilian Amazon region who had had vivax malaria at the age of 11 months was admitted
three months later with a history of progressive dyspnoea and fever, which culminated in respiratory distress and
severe dilated cardiomyopathy at hospital admission in a malaria-free area. She received treatment for cardiac
insufficiency and was tested for malaria with two thick blood smears, which were negative. There was general
improvement of cardiorespiratory function in the next two weeks, but in the third week of hospital admission, there
was re-appearance of fever, severe anaemia, severe plaquetopaenia, and respiratory distress. A third thick blood
smear was positive for Plasmodium vivax mono-infection, which was confirmed by molecular methods. A
serological panel with the most prevalent infectious agents known to cause myocarditis was performed, and
specific anti-cytomegalovirus (CMV) IgM and elevated levels of anti-CMV IgG were also detected in the serum. After
treatment for malaria, there was improvement of respiratory distress, although cardiac function did not recover. She
was discharged home with drugs for cardiac insufficiency and is currently under follow-up with a paediatric
cardiologist as an outpatient. This report presents a young child with several episodes of vivax malaria who suffers
from cardiac insufficiency, probably related to CMV-induced myocarditis.
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Vivax malaria is an important disease responsible for up
to 400 million infections in endemic areas of Asia, Latin
America, and some parts of Africa. In recent years, it
has been shown that this so-called benign malaria can
result in severe presentation with multiple organ dys-
function and life-threatening disease. The majority of se-
vere vivax malaria cases have been reported in India
[1-4], but many cases occurred in other countries where
there is active transmission, such as Ethiopia [5], Sudan
[6], Cambodia [7], Colombia [8], and Brazil [9-12]. Cri-
teria for diagnosing severe vivax malaria, as opposed to
severe falciparum malaria, are still not clearly defined,
since some biological features of these two parasites are
different, and in the meantime the WHO definition for
severe falciparum malaria is used [13].* Correspondence: msnunes1@yahoo.com.br
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unless otherwise stated.Vivax malaria is an important morbidity in children
living in countries with endemic transmission. At the
same time, children are also susceptible to other infec-
tions, such as viral diseases, because they still lack spe-
cific immunity to most of the pathogens in their first
years of life, and co-morbidities can occur, especially in
underdeveloped and developing regions, such as the
Amazon.
This is the report of a case of acute myocarditis and
dilated cardiomyopathy associated with cytomegalovirus
(CMV) infection and vivax malaria in an infant residing
in the Brazilian Amazon region.Case report
A 13-month old girl living in the rural area of Cruzeiro
do Sul, in Acre state (a small town of 73,000 inhabitants
that notified 16,500 malaria cases in 2012) was admitted
to a local hospital facility on September 9th, 2013 with a
complaint of shortness of breath for approximately
30 days prior to the admission. Her parents referred to
productive cough and fever in the preceding days. HerLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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day hospital admission at the age of 11 months (June
2013) for respiratory symptoms, which were considered
to be ‘pneumonia', according to parents report. Since
she had fever and lived in an area of malaria transmis-
sion, she was tested for malaria. Malaria records showed
that she was diagnosed with vivax malaria, confirmed by
microscopy. Malaria treatment was initiated with oral
chloroquine (25 mg/kg over three days) and primaquine
(0.5 mg/kg/day over seven days) while she was in the
hospital, and primaquine treatment was completed later
at home, according to parents’ report. She had been
born full-term, 3,695 kg in weight and 50 cm in length,
from caesarean surgery. Her mother denied attending
prenatal care during pregnancy.
At hospital admission, she had signs of respiratory dis-
tress on physical examination, with wheezing, crackles,
and nasal flare. Heart rate was 129 bpm, respiratory rate
was 26 ipm. She measured 72 cm in length and her
weight was 9 kg. There was mild hepatomegaly. During
the next three days, her heart rate escalated to 162 bpm,
respiratory frequency varied between 26 and 50 bpm,
and axillary temperature ranged from 37 to 37.8°C.
Based on signs of respiratory distress and productive
cough, there was an initial diagnosis of pneumonia and
she was started on ceftriaxone on the day of admission.Figure 1 Electrocardiogram in a child with dilated cardiomyopathy. TThe electrocardiogram showed sinus rhythm, left ven-
tricular overload and left atrial overload (Figure 1). Chest
X-ray showed pulmonary congestion and enlarged car-
diac area (Figure 2). A thick smear for malaria diagnosis
was negative on September 11th. According to the proto-
col stipulated by the Ministry of Health, 100 high power
fields were examined before a negative diagnosis was is-
sued. Unfortunately, rapid diagnostic tests for malaria
were not available at the hospital at this time.
Because of her critical conditions, she was referred to
a larger hospital in another city (Rio Branco) on Septem-
ber 13rd, with a diagnosis of cardiac failure of unknown
origin, where she was seen by a paediatric cardiologist.
On examination, she had severe dyspnoea (50 ipm) and
a regular tachycardic heartbeat (140 bpm), with hypopho-
netic heart sounds. The first echocardiogram, performed
on September 14th, showed dilated cardiomyopathy with
severe systolic dysfunction: mildly dilated left atrium
(27.2 mm), severely dilated left ventricle (60 × 50 mm),
ejection fraction of 35%, severe mitral insufficiency, mild
aortic valve insufficiency, and no signs of cardiac malfor-
mation. Laboratory examinations showed normal erythro-
cyte sedimentation rate, negative C-reactive protein test,
normal CPK (26 U/l, range 26–155 U/l), increased value of
CK-mB (42 U/l, normal: less than 25 U/L), AST 42 U/l,
ALT 21 U/l. A haemogram revealed anaemia (haemoglobinhe electrocardiogram shows left ventricular and atrial overload.
Figure 2 Chest radiography showing cardiomegaly. There is marked
dilation of the left ventricle and increased pulmonary blood flow.
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57% of granulocytes and 46% of lymphocytes, with normal
platelet count (370,000/mm3). Another blood thick smear
for malaria was performed on September 13rd, using the
same criteria described before, which was also considered
to be negative. She continued to receive ceftriaxone, and
she was started on carvedilol, digoxin, furosemide, capto-
pril, spironolactone, and oxacilin.
Between September 13rd and 17th she remained in
stable condition with gradual decrease of heart rateFigure 3 Molecular diagnosis of Plasmodium vivax infection. A DNA sa
for P. vivax mono-infection. PS = Patient sample; VPC = P. vivax positive con
weight marker.(from 130 to 100 bpm) and respiratory rate (from 50 to
28 ipm). There was also disappearance of other clinical
signs of respiratory distress.
On September 17th, she had diarrhoea with liquid stools
which lasted nine days, with up to seven evacuations per
day, accompanied by low-grade fever (37.2-37.6°C). On 19
September, the CKmB levels returned to normal (19.20
U/l). Ceftriaxone was terminated on September 20th
but the patient continued to present low-grade fever in
the next days.
Ceftazidime and vancomycin were started on September
23rd, because fever did not cease and clinical conditions
were getting worse day by day even after a full course of
Ceftriaxone, making the clinicians very worrisome about
her clinical status Diarrhoea ceased after three days of
vancomycin, but axillary temperature continued to raise
and reached 38.5°C despite antibiotic administration. On
September 29th, she was started on dipirone every six
hours; haemoglobin values were 8.3 g/dL. OnOctober 3rd
haemoglobin values had decreased to 6.6 g/dL, when she
received a blood transfusion because of the acute drop in
haemoglobin levels. There was worsening of dyspnoea
(from 30 to 42 ipm) and tachycardia (from 110 to
124 bpm), and on October 4th, another thick blood
smear for malaria was performed, which was positive
for P. vivax, with approximately 10,000 parasites/mm3.
Molecular diagnosis of Plasmodium species was per-
formed using nested polymerase chain reaction [14,15],
and it confirmed a mono-infection by P. vivax (Figure 3).
Glucose levels were 74 mg/dL at this point. Standardized
treatment with chloroquine (25 mg/kg over three days) and
primaquine (0.5 mg/kg/day over seven days) according to
Brazilian Ministry of Health [16] was started. Aftermple of the patient was submitted to nested PCR and it was positive
trol; FPC = P. falciparum positive control; B = Blank; M = Molecular
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ever, a day later haemoglobin had decreased again to
7.7 g/dL and platelet count was 47,000/mm3. The patient
was clinically anicteric, but no laboratory measurement
of bilirubin was performed. Table 1 shows the result of
haemograms and Figure 4 shows the relationship between
fever, haemoglobin levels and platelet counts. After
malaria diagnosis, the patient started to receive hourly
antipyretics.
A panel of serologic tests for the most common infec-
tious agents known to cause myocarditis in children
was performed. Anti-CMV antibodies were detected on
October 4th (IgM of 2.66 for a cut-off > = 1.0 and IgG
higher than 250, cut-off > 6.0), and six days later, IgM
titres increased to 9.34 (cut-off > = 1.0). Laboratory inves-
tigation for other infectious agents (hepatitis B, hepatitis
C, HIV, Epstein Barr virus, Toxoplasma gondii, Trypa-
nosoma cruzi) were negative on two separate samples
(October 4th and October 10th). It was decided not to use
gancyclovir because there was no evidence of possible
clinical benefit at this point and since this drug can
cause bone marrow toxicity, it may have exacerbated the
anaemia and thrombocytopaenia if it had been used [18].
Fever resolved on day 3 of chloroquine + primaquine
treatment (October 6th) and dyspnoea improved from
7th October onwards. There was a progressive significant
clinical improvement with disappearance of respiratory
distress between October 7th and 14th. Despite this clinical
improvement, cardiac echocardiogram remained mostly
unchanged. A second echocardiogram performed on
October 1st showed dilated cardiomyopathy with severeTable 1 Haemoglobin levels, leukocyte and differential count
10 September and malaria treatment in early October, 2013
Haemoglobin
(mmol/l)
Leukocytes (mm3) Segmented
neutrophils %
Lymp
10/9 9.7 13,800 32
12/9 9.7 7,900 45
13/9 9.69 10,900 57
13/9 10 14,900 48
15/9 9.7 10,600 31
23/9 9.5 32,200 70
26/9 9.5 9,500 53
27/9 9.7 8,400 42
29/9 8.3 9,200 56
3/10 6.6 12,100 53
4/10 9.5 9,600 49
5/10 7.4 7,400 33
6/10 7.7 14,800 32
Reference values for 6 months to 2 years old children: 10.5 to 13.5 g/dL haemoglob
lymphocytes [17].systolic dysfunction, increased dilation of left atrium
(31.9 cm), severe distension of left ventricle (48 cm ×
39.5 cm), ejection fraction of 36% and severe mitral
valve insufficiency. CMV IgM was 1.44 on October 25th.
The third echocardiogram performed on November 1st
showed severe dilation of left atrium (31 mm, Z score +
4.35), severe dilation of left ventricle (54 mm, Z score +
9.43), moderate mitral valve insufficiency secondary to
ventricle dilation, severe systolic dysfunction with an
ejection fraction of 41% and myocardial performance
index of 1.03 (defined as the sum of isovolumetric con-
traction and relaxation time divided by the ejection time)
(Figures 5 and 6). She continued to improve clinically and
remained without clinical signs of respiratory distress des-
pite maintaining cardiac dysfunction, and was kept on
close treatment follow-up with prescription of furosemide,
captopril, spironolactone, digoxin, and carvedilol. Figure 7
illustrates the most important events of the case.
Discussion
The main features of this case are the dilated cardiomy-
opathy associated with respiratory distress and vivax
malaria that presents later on the course of the disease.
The cause of the dilated cardiomyopathy is problably
CMV-induced myocarditis. Myocarditis can be acute,
subacute or chronic, and it is characterized by a variety
of symptoms, ranging from mild chest pain to cardiac
shock and sudden death. In children, the most common
symptoms are dyspnoea, vomiting, fever, and lethargy.
Most of paediatric myocarditis is not recognized at the
beginning, making the diagnosis even more difficult.s, and platelet counts between initial admission on
hocytes % Platelets (*109/l) Important
clinical events
57 366 Dyspnoea,
starts Ceftriaxone
49 292
41 388
46 370
54 311
16 299 Diarrhoea since 17/9;
starts Ceftazidime + Vancomycin
36 320
46 224 Fever 38.5°C
38 300
13 102 Blood transfusion after haemogram
38 361 Smear positive for P. vivax
48 47
48 79
in, 6,000– 17,500 leucocytes/μL, 15-35% segmented neutrophils, 45 – 6775%
Figure 4 Clinical evolution of fever, platelet counts and haemoglobin and its relation with malaria. On admission (10/9) haemogobin
level was 9.7 mmol/l and platelet count was normal. After a few days of admission axillary temperature increased, peaking on 29/9, when hourly
antipyretics were prescribed. Four days later there was an acute drop on haemoglobin levels and platelet counts. The patient received a blood
transfusion on 3/10, resulting in increased platelet count and haemoglobin levels. However, they declined again on 5/10. A positive smear for
P. vivax was obtained in 4/10.
Figure 5 Four-chamber echocardiographic image showing
marked dilation of the left ventricle. RA = right atrium, LA = left
atrium, RV = right ventricle, LV = Left ventricle.
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tricular and atrial overload are seen with the progression
to dilated cardiomyopathy. In severe cases, cardiac insuffi-
ciency may develop because of acute severe injury or
resulting dilated cardiomyopathy. In these cases, tachycar-
dia, tachypnea and respiratory distress are frequent [19].
Although the gold standard examination for diagnosing
myocarditis is myocardial biopsy, this procedure is not
often performed. Ancillary diagnostic examinations in-
clude eletrocardiogram, echocardiogram and magnetic
resonance of the heart [20]. Paediatric myocarditis are
mostly caused by viral infections, namely enteroviruses
(Coxsackie virus, echovirus and poliovirus). Other viruses
are also associated with this lesion, such as parvovirus B
19, herpesvirus 6, influenza, para-influenza, adenovirus,
Epstein Barr virus, and CMV. Less frequently, other non-
viral agents, such as Toxoplasma gondii and Trypanosoma
cruzi, can also cause acute myocarditis [21].
This child presented serial venous samples with in-
creasing titres of seric IgM anti-CMV and high titres of
IgG during admission. Studies on window interval with
blood donors and blood recipients [22], and naturally in-
fected immuno-competent patients [23] show that CMV
genes are readily detectable while CMV-specific anti-
bodies will take between three and five weeks after infec-
tion to be detected, supporting the hypothesis of CMV-
Figure 6 Echocardiographic image showing marked dilation of the
left ventricle and mitral regurgitation (in blue) of moderate degree.
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show that IgM can take up to eight weeks to be detect-
able [24].
Several authors have described CMV-induced myocardi-
tis. Evidence of CMV infection in ‘idiopathic’ dilated cardio-
myopathy has also been shown [23,25]. A case of dilated
cardiomyopathy in a two-month old infant with congenital
CMV infection shows that progression from myocarditis
to cardiomyopathy can occur in a few months [26], and
that CMV specific IgM antibodies can be detectable at
least 16 weeks after myocarditis has occurred [26].Figure 7 Patient history with major clinical events, diagnosis and pos
11 months old with respiratory symptoms and vivax malaria. She was treat
months she started to have increasing dyspnoea and respiratory distress an
cardiomyopathy and negative thick blood smears. During admission, there
dyspnoea worsened and she developed fever, with a positive smear to P. v
was important improvement of respiratory distress and fever. Positive serology
11 months of age, progressing to symptomatic dilated cardiomyopathy, and laIt is possible that in this patient, CMV infection and
acute myocarditis started in June, at the time of her first
hospital admission, and that it was misdiagnosed as
pneumonia because of respiratory symptoms. It has been
shown that CMV can simulate pneumonia because of
pronounced pulmonary congestion [25]. As pulmonary
congestion and other symptoms of cardiac insufficiency
increased and she progressed to dilated cardiomyopathy,
the diagnosis of cardiac injury was made and she was re-
ferred to a larger hospital where other examinations and
a proper diagnosis could be made.
The evolution of acute myocarditis to dilated cardiomy-
opathy has been explained by the occurrence of inflamma-
tory lesion to the myocardial cell and adverse remodelling
resulting in dilated cardiac chambers [27,28]. Experimen-
tal studies suggest that CMV infects the myocardial cell,
which are then attacked by macrophages and natural killer
cells, and later on by T lymphocytes, around 15 and
30 days post-infection [28,29]. After that, there is progres-
sion to fibrosis, cavity enlargement and heart failure, be-
tween 30 and 90 days post-infection [28], with persistence
of viral genome in the heart even after 90 days of infection
[28]. Sakaguchi et al. [26] described a case of congenital
infection in which impaired cardiac function was detected
at 30 weeks of gestation already. In the present case re-
port, the time between the first hospital admission with
fever and respiratory symptoms, and the respiratory dis-
tress leading to the second hospital admission was be-
tween four to eight weeks, supporting the hypothesis that
this was a case of CMV-induced myocarditis progressing
to dilated cardiomyopathy.sible causal relationship. The patient was admitted when she was
ed and discharged home two days later without symptoms. After two
d was admitted again at 13 months old with a dilated
was an initial improvement of dyspnoea, but after a few weeks the
ivax. After malaria treatment with chloroquine and primaquine, there
for CMV suggest that she had a CMV-induced myocarditis around
ter developing relapsing vivax malaria, with a severe clinical presentation.
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this child also developed vivax malaria. Criteria for rec-
ognizing severe vivax malaria are now being discussed in
the literature. Series of case reports and review of litera-
ture show a range of clinical and laboratory findings that
are frequently seen in patients with severe vivax malaria
[10,11,30]. These parameters included severe thrombo-
cytopaenia [31,32], variable degrees of anaemia [5,33,34]
(including severe anaemia with haemoglobin level <5 g/dL),
lung injury with respiratory distress (mainly in children)
[2,5,30,35,36], renal failure and jaundice [31,33,37], and
less frequently, coma or cerebral malaria [2]. In this case,
there was an acute drop in haemoglobin levels, together
with worsening of respiratory symptoms. Although these
changes do not meet the criteria currently used for severe
malaria, the appearance of this second episode of vivax
malaria contributed to worsening of clinical conditions.
In this case, the patient was already in respiratory dis-
tress, possibly as a result of CMV infection leading to di-
lated cardiomyopathy and pulmonary congestion, which
worsened with the appearance of peripheral Plasmodium
parasitaemia. Interestingly, treatment of malaria reduced
the respiratory distress substantially, which confirms the
role of Plasmodium in increasing the previous pulmonary
injury she presented at admission. The mechanism of
vivax-induced respiratory distress is currently attributed
to cytoadherence to the lung microvasculature [38] and
increased permeability of the alveolar-capillary membrane
caused by sequestration and inflammatory response to
the Plasmodium and its treatment [39], which is sup-
ported by post-mortem findings in Brazil [40]. On the
other hand, malaria can also impairs cardiac function.
Tachycardia, diminished ejection fraction and impaired
left ventricular function were frequent in Kenyan chil-
dren with severe falciparum malaria, and after treatment
a significant improvement in cardiac function was ob-
served. The aetiology of such cardiac depression is not
clear, and may be related to cytokine release, acidosis,
hypovolaemia or sequestration of red cells in myocardial
vessels [41]. There are a few other reports of myocardial
dysfunction caused primarily by malaria, all of them re-
lated to severe Plasmodium falciparum infection [42-44]
and one caused by experimental malaria [45].
This one-year old child had a vivax malaria episode in
June and another episode in October. Since she had a
prolonged admission stay (23 days) with two negative
thick blood smears and there is no malaria transmission
in Rio Branco (where the hospital was located), it is
highly possible that the patent parasitaemia detecting on
4 October, and the preceding seven days of fever, were
the result of hypnozoite reactivation. Vivax malaria
treatment was administered orally and it is possible that
treatment with primaquine at home was not adequate in
June, which would favour early relapse when facing asystemic disease [46]. It is less likely that recrudescence
would occur, since chloroquine treatment was per-
formed inside the hospital and most of recrudescence
cases are seen within a month after incomplete treat-
ment.There is scarce data on vivax relapses in the Brazilian
Amazon. In 1991, Boulos et al. [47] estimated a 7% rate of
relapsing vivax episodes, occurring up to 90 days after the
first episode. There are no other recent reports for data
comparison. Since albeit had not been possible to do rapid
diagnostic tests or molecular testing for malaria before
October 4th, it is conceivable that she had a very low P.
vivax parasitaemia that was missed at hospital admission,
but even in this situation, a relapsing malaria would be
feasible due to improper treatment in June. In Brazil, ac-
cess to anti-malarials is controlled by the Ministry of
Health, and chloroquine usage is only allowed in two very
defined situations: following a positive diagnostic test or
as prophylaxis for recurrent vivax malaria after the second
episode when primaquine cannot be used (children under
6 months of age and pregnant women) [16].
It is described that repeated episodes of malaria can
cause the removal of both infected and uninfected red
blood cells, which could explain the anaemia observed at
the second hospital admission, together with some de-
gree of iron deficiency caused by low intake. The sub-
stantial drop of haemoglobin levels around October 4th,
on the other hand, is directly related to the severity of
vivax malaria [30], and can be caused by haemolysis, im-
paired haemopoiesis or spleen sequestration. This child
also presented lymphopaenia, detected in October 3rd,
one day before she had a positive thick smear form mal-
aria. Although it is not a correlate of severe disease, lym-
phopaenia is frequent in malaria patients [48].
The aetiology of diarrhoea was not formally investigated,
but it is possible that she had an antibiotics-associated col-
itis, or even Clostridium difficile-associated diarrhoea.
Clostridium difficile diarrhoea is the most common cause
of diarrhoea associated with antibiotic usage, and the most
common symptoms in children are liquid stools that re-
solve in 30 days, while adults tend to have pseudomem-
branous colitis much more frequently [49]. This child was
started empirically on vancomycin and diarrhoea resolved
three days later, while fever continued to exist. Changes in
haemogram from September 23rd showed increased
leucocyte count with increased segmented neutrophils,
supporting the hypothesis of an antibiotic-associated C.
difficile diarrhoea [49].
Technical limitations that are common in the Amazonian
health care system prevented a more detailed investigation
of the case. Malaria smears should have been performed
earlier and more often during the course of admission in
this case, and maybe this would have prevented the acute
drops in haemoglobin levels and platelet numbers, and
the worsening of cardiorespiratory function. The aetiology
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conditions will make the follow-up of this child with
cardiac insufficiency more difficult, since at her home
area there is no cardiologic health care available. It is
worth pointing out that in malaria-endemic settings,
socio-economic inequalities can facilitate the occur-
rence of co-morbidities and at the same time may hin-
der proper health care.
Conclusion
This case portrays the concomitance of two important in-
fectious diseases in a young child. While CMV infection is
a cosmopolitan infectious agent, vivax malaria is a disease
associated with social inequities, and should be investi-
gated in all patients with similar settings. Health care pro-
vided to this patient at the beginning of clinical course
was limited because of inherent health care access in the
Amazon, but despite that, medical efforts were able to
keep her health condition stable.
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